Morgan Stanley has published a report on Johnson & Johnson JNJ broadly commenting on the company.
In the report, Morgan Stanley wrote, "We're not overly alarmed by 2H11 EBIT shortfall. Though the quarter does raise some questions on long-term leverage potential, the reduction in operating profit implied in updated guidance may reflect timing of near-term investments or an opportunistic decision to reinvest unanticipated upside from a lower tax rate. We continue to model EPS growth acceleration from 4.2% in 2011 to 8.0% in 2012 and 7.2% in 2013."
Morgan Stanley rated Johnson & Johnson an Equal-weight and did not give a price target. Johnson & Johnson closed Tuesday at $66.72.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in